ZTlido Approval History
FDA Approved: Yes (First approved February 28, 2018)
Brand name: ZTlido
Generic name: lidocaine
Dosage form: Patch
Previous Name: Ztilido
Company: Scilex Pharmaceuticals, Inc.
Treatment for: Postherpetic Neuralgia
ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with postherpetic neuralgia.
Development History and FDA Approval Process for ZTlido
|Feb 28, 2018|| Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain|
|Sep 12, 2017||FDA Acknowledges Receipt of Sorrento Therapeutics Inc, NDA for ZTlido|
|Aug 29, 2017||Sorrento Therapeutics, Inc. Submits NDA For ZTlido Next-Generation Lidocaine Patch|
|Sep 16, 2015||FDA Accepts Scilex Pharmaceuticals' NDA Filing for ZTlido|
|May 15, 2014||Scilex Pharmaceuticals Initiates Pivotal Pharmacokinetic Study for Ztilido|
|Mar 24, 2014||Scilex Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztilido|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.